Aims and outcomes
Tumour, cancer, tumour
TUMOUR, CANCER, SECONDARY, TUMOUR
The primary objective of this study is to establish the maximum tolerated non-tumourous liver-absorbed dose of Secondary aims include establishing a dose–response relationship between (i) the perfused/treated normal liver-absorbed dose and the FLR response and (ii) the tumour-absorbed dose and the tumour response, to map the safety and feasibility of surgical resection of converted patients, and to assess quality of life during the study procedures. FLR response will be quantified using MRI (volume of the FLR) and hepatobiliary iminodiacetic acid (HIDA) scan (function of the FLR). Tumour response will be assessed using the mRECIST criteria [As a last secondary aim, a biobank will be generated of resected liver specimens and blood samples for future analyses of therapy surviving cancer cells.